Milestone Scientific Launches CompuFlo Advisor Program

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Feb 23 2026

0mins

Should l Buy MLSS?

Milestone Scientific announced the launch of the CompuFlo Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimize long-term Medicare reimbursement rates. The program, which commenced on February 1, 2026, targets high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor jurisdictions, including Novitas, First Coast, Noridian, and Palmetto. These jurisdictions represent a strategic first phase of execution, with infrastructure designed to support phased expansion across additional MAC regions throughout the United States. By engaging Key Opinion Leaders to generate a targeted 1,000-2,000 case submissions in the initial six-month phase, Milestone is executing a structured clinical and reimbursement roadmap to transition CPT code 0777T from Category III to Category I status, that could enhance commercial adoption and long-term revenue visibility.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy MLSS?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on MLSS

Wall Street analysts forecast MLSS stock price to rise

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.288

Low

1.00

Averages

1.00

High

1.00

Current: 0.288

Low

1.00

Averages

1.00

High

1.00

Benchmark

Speculative Buy

downgrade

2025-11-20

Reason

Benchmark

Price Target

AI Analysis

2025-11-20

downgrade

Speculative Buy

Reason

Benchmark lowered the firm's price target on Milestone Scientific to $1 from $1.25 and keeps a Speculative Buy rating on the shares. Sales traction for the Medical business has proven to be elusive, so the firm is lowering its forward revenue estimates, noting that its 2030 revenue estimate of $22M is discounted to the end of 2026 at 8.2% to arrive at its lowered price target.

About MLSS

Milestone Scientific Inc. is a biomedical technology company. The Company patents, designs, develops and commercializes diagnostic and therapeutic injection technologies and devices for medical and dental use. The Company operates through two segments: dental and medical. The Company has developed a computer-controlled anesthetic delivery device, its DPS Dynamic Pressure Sensing Technology System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration. Its device, using The Wand, a single-use disposable handpiece, is marketed in dentistry under the trademarks CompuDent and STA Single Tooth Anesthesia System, and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in over 41 other countries. In addition, the Company has obtained CE mark approval for certain medical devices, which can be marketed and sold in various European countries.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Milestone Scientific Releases 2026 Outlook with Revenue Growth Expectations

18 hours agoseekingalpha

Earnings Report: Milestone Scientific reported a FY GAAP EPS of -$0.07, aligning with expectations, while revenue of $8.97 million, a 3.9% year-over-year increase, fell short of the $9.00 million consensus, indicating challenges in revenue growth.
2026 Outlook: Management anticipates total revenue for 2026 to range between $9.8 million and $10.2 million, although below the consensus of $9.91 million, reflecting expected double-digit growth driven by broader commercial adoption in both dental and medical sectors.
CompuFlo Revenue Forecast: For 2026, CompuFlo revenue is projected to be between $500,000 and $600,000, representing an approximate 400% increase over 2025, highlighting strong growth potential in specific product lines that may attract investor interest.
Cost Structure Optimization: Coupled with structural cost reductions implemented in 2025, the anticipated revenue growth in 2026 is expected to yield improved operating leverage and a significant reduction in cash burn compared to the previous year, enhancing the company's financial health.

Milestone Scientific Reports Q4 2025 Earnings and Future Guidance

10 hours agoYahoo Finance

Revenue Growth: Q4 2025 revenue reached $2.1 million, a 2.2% increase from $2 million in Q4 2024, indicating stability in the market despite modest growth, which may present future opportunities.
Improved Operating Loss: The operating loss for Q4 2025 was $1.1 million, an 89% improvement from $2 million in Q4 2024, demonstrating significant progress in cost control and operational efficiency.
Future Guidance: The 2026 revenue guidance is set between $9.8 million and $10.2 million, reflecting expectations of double-digit year-over-year growth, showcasing the company's confidence in future market demand and strategic positioning.
International Market Expansion: Milestone Scientific's dental business is gaining traction in countries like Japan, India, and Mexico, indicating the company's proactive approach to seeking growth opportunities in international markets to enhance its global competitiveness.

Milestone Scientific Q4 2025 Earnings Call Insights

14 hours agoseekingalpha

Management Restructuring: CEO Eric Hines, who took over in August 2025, immediately scrutinized company expenditures, cutting non-revenue-generating costs to ensure effective resource utilization, thereby laying a foundation for future growth.
Revenue Growth Outlook: Management projects total revenue for 2026 to be between $9.8 million and $10.2 million, reflecting double-digit year-over-year growth primarily driven by continued adoption in international markets and dental products, indicating the company's market potential.
CompuFlo Initiative: Hines emphasized that the CompuFlo system will be a key growth driver, with expected contributions of $500,000 to $600,000 in 2026, representing approximately a 400% increase over 2025, which will significantly enhance the company's competitive position in the market.
Cash Flow Target: Management has set a goal to achieve cash flow breakeven by early 2027, and combined with cost control measures from 2025, this is expected to significantly improve operating leverage and reduce cash burn, enhancing the company's financial stability.